Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $113
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $109 to $113.
September 06, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Ascendis Pharma and raises the price target from $109 to $113.
The news is directly related to Ascendis Pharma. The raised price target by Morgan Stanley indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100